Pancreatic Neoplasm — Variants & evidence

Pancreatic Neoplasm — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

152 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 151–152 of 152 evidence items (2 on this page mapped to a descendant entity) · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
NTRK1 Fusion2
Larotrectinib	Malignant Pancreatic Neoplasm	Predictive	C	Supports Sensitivity Response	3	submitted	EID7649 A patient with pancreatic cancer harboring NTRK fusion was treated with larotrectinib. The best overall response was PR at 2 months but the tumor progressed after 6 months. PMID 31605106 · O'Reilly et al., 2019 · Open in CIViC	civic
〃	Malignant Pancreatic Neoplasm	Predictive	C	Supports Sensitivity Response	2	submitted	EID6051 In a Phase I/II study of Larotrectinib, highly selective TRK inhibitor, one patient with pancreatic cancer with NTRK fusion showed PR. PMID 29466156 · Drilon et al., 2018 · Open in CIViC	civic

Data updated 17 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.